Company intelligence / Profile preview

BioBetter

Kiryat Shmona, Northern District, Israelbiobetter.bio ↗

Ownership: Private
Development stage: Commercial

Overview

BioBetter has developed a scalable plant-based platform to express and purify complex recombinant proteins—primarily targeting the cultivated meat industry by supplying affordable animal-free growth factors. The company claims dramatic cost reductions compared to traditional methods, with a pilot facility capable of producing up to 100 kg/day of purified protein. The technology has also been demonstrated with pharmaceutical biologics such as adalimumab ("Humira"), though no commercial drug products are yet approved.

Therapeutic areas: OtherImmunology
Modalities: Recombinant proteins (including growth factors and monoclonal antibodies)Biologics
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on BioBetter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioBetter.

Explore the full profile